利伐沙班预防全髋关节置换术后静脉血栓的近期疗效及安全性

The Laval Shaaban Prevention of Venous Thromboembolism After Totalhip Replacement in the Near Future Curative Effect and Security

目的研究全髋关节置换后预防静脉血栓使用的利伐沙班与依诺肝素的近期疗效及安全性。方法整群选取2014年3月—2015年1月该院收治的84例初次全髋关节置换手术的病例,随机对照分为利伐沙班组42例,依诺肝素组42例。观察术后有无发生非致死性PE事件、深静脉血栓、死亡事件,术中及术后输血率和出血量。结果利伐沙班组的深静脉血栓(deep venous thrombosis,DVT)出现了10例,依诺肝素组的DVT出现了9例,在两组患者中都没有发生肺栓塞及PE事件,两组患者的DVT发病率差异无统计学意义(χ2=0.204,P=0.651)。两组患者围手术期的隐性失血量、输血率及总失血量差异无统计学意义(P>0.05),安全性类似。结论利伐沙班预防THA术后VTE与依诺肝素无明显差异,且利伐沙班较伊诺肝素安全性更高。

Objective To study the prevention of venous thromboembolism after total hipreplacement with the advantages of cutting shaaban and in accordance with the presence of heparin in the near future curative effect and safety of selection. Methods March2014 to January 2015, our hospital 84 cases of primary total hip replacement surgery, randomizedinto the cutting team 42 cases, in accordance with the heparin group of 42 cases.To observe the postoperative presence of nonfatal PE events, deep vein thrombosis,deaths, intraoperative and postoperative blood transfusion rate and the blood loss. Results Benefit fellingsand shift of deep vein thrombosis(deep venous thrombosis, DVT) in 10 cases, in accordance with DVT appeared 9 cases, heparin group, didn’t happen in the two groups of patients with pulmonary embolism and PE events, there were no significant difference on twogroups of patients with DVT incidence(χ2=0.204,P=0.204).Two groups of patients with perioperative hidden blood loss, transfusion rate and total blood loss there was no significantdifference(P>0.05), and security. Conclusion The laval shaaban THA postoperative VTEprevention and in accordance with heparin has no obvious difference.And the cut shaaban is eno heparin security is higher.